Edwards Lifesciences Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss decreased by 16.5% to $39.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 26.2%, from $53.00M to $39.10M.
An increase indicates a shift toward long-term, stable income generation, while a decrease suggests maturing assets or a change in investment strategy.
This represents the amortized cost of debt securities that the company has the positive intent and ability to hold until...
Common in insurance companies with long-duration liabilities.
non_current_assets_debt_securities_held_to_maturity_amor_ede40c| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $35.00M | $83.00M | $160.00M | $65.20M | $123.00M | $28.00M | $28.10M | $28.00M | $56.00M | $53.40M | $50.50M | $53.00M | $44.70M | $46.80M | $39.10M |
| QoQ Change | — | +137.1% | +92.8% | -59.3% | +88.7% | -77.2% | +0.4% | -0.4% | +100.0% | -4.6% | -5.4% | +5.0% | -15.7% | +4.7% | -16.5% |
| YoY Change | — | — | — | +86.3% | +48.2% | -82.5% | -56.9% | -77.2% | +100.0% | +90.0% | +80.4% | -5.4% | -16.3% | -7.3% | -26.2% |